Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. AGEN
AGEN logo

AGEN Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Agenus Inc (AGEN) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
4.420
1 Day change
-7.83%
52 Week Range
7.340
Analysis Updated At
2026/04/16
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Agenus Inc (AGEN) is not a strong buy at the moment for a beginner investor with a long-term strategy. The technical indicators are neutral, there are no significant positive catalysts, and the financial performance shows declining profitability. While options data indicates bullish sentiment, the lack of recent news or significant insider/hedge fund activity, coupled with weak financials, suggests holding off on investment until clearer positive signals emerge.

Technical Analysis

The MACD is positive but contracting, indicating weakening momentum. RSI is neutral at 66.365, and moving averages are converging, suggesting no clear trend. The stock is trading below its pivot point of 4.177, with key resistance at 4.88 and support at 3.474.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

The open interest put-call ratio and option volume put-call ratio both indicate bullish sentiment. However, the implied volatility rank is low at 18.93, suggesting limited market excitement.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
3
Buy
7

Positive Catalysts

  • Options data shows bullish sentiment, and the stock has a 7.23% chance of gaining in the next month based on historical patterns.

Neutral/Negative Catalysts

  • No recent news or significant insider/hedge fund activity. Financial performance shows declining net income (-76.84% YoY) and EPS (-84.50% YoY). Congress trading data is unavailable.

Financial Performance

In 2025/Q4, revenue increased by 27.45% YoY to $34.2M, but net income dropped by 76.84% YoY to -$10.63M. EPS declined by 84.50% YoY to -0.31, indicating worsening profitability. Gross margin improved slightly to 100%.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No recent analyst rating or price target changes available.

Wall Street analysts forecast AGEN stock price to rise
1 Analyst Rating
Wall Street analysts forecast AGEN stock price to rise
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 4.790
sliders
Low
23
Averages
23
High
23
Current: 4.790
sliders
Low
23
Averages
23
High
23
H.C. Wainwright
H.C. Wainwright
Neutral -> Buy
upgrade
$25
AI Analysis
2025-06-04
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$25
AI Analysis
2025-06-04
upgrade
Neutral -> Buy
Reason
H.C. Wainwright upgraded Agenus to Buy from Neutral with a $25 price target after the company entered into a strategic collaboration with Indian multinational pharmaceutical company Zydus Lifesciences. The definitive partnership is valued at up to $141M and is aimed at accelerating the clinical development of botensilimab and balstilimab while also securing scaled manufacturing both domestically and outside the U.S., the analyst tells investors in a research note. Th firm says that given Agenus' commitment to reducing its cash burn and the capital provided from this partnership, it now believes the company has sufficient funding to advance botensilimab and balstilimab through a Phase 3 trial initiating in the second half of 2025.
Baird
Baird
Neutral
maintain
$4 -> $6
2025-06-04
Reason
Baird
Baird
Price Target
$4 -> $6
2025-06-04
maintain
Neutral
Reason
Baird raised the firm's price target on Agenus to $6 from $4 and keeps a Neutral rating on the shares. The firm updatedits model following the receipt of ts $91M upfront payment from its strategic collaboration with Zydus.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for AGEN
Unlock Now

People Also Watch